Inhibition of osteoblast function in vitro by aminobisphosphonates

Journal of Cellular Biochemistry

Volumn 106, Issue 1, 2009, Pages 109-118

  Orriss, Isabel R ^a   Key, Michelle L ^a   Colston, Kay W ^b   Arnett, Timothy R ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Bisphonates; Bone formation; Mineralisation; Osteoblasts; Zoldronate

Indexed keywords

ALKALINE PHOSPHATASE; CLODRONIC ACID; COLLAGEN; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ANIMAL CELL; ARTICLE; BONE MINERALIZATION; CALVARIA; CELL CULTURE; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DENTIN; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME INHIBITION; IN VITRO STUDY; NONHUMAN; OSSIFICATION; OSTEOBLAST; PRIORITY JOURNAL; RAT; TRABECULAR BONE;

ALKALINE PHOSPHATASE; ANIMALS; BONE DENSITY CONSERVATION AGENTS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; DIPHOSPHONATES; IMIDAZOLES; OSTEOBLASTS; OSTEOGENESIS; RATS;

RATTUS;

EID: 58649122908     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21983     Document Type: Article

References (31)

1. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ. 2003. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207-1215.
2. Brandao-Burch A, Utting JC, Orriss IR, Arnett TR. 2005. Acidosis inhibits bone formation by osteoblasts in vitro by preventing mineralization. Calcif Tissue Int 77:167-174.
3. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ. 1997. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100: 1475-1480.
4. Delmas PD, Vergnaud P, Arlot ME, Pastoureau P, Meunier PJ, Nilssen MH. 1995. The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate-Is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? Bone 16:603-610.
5. Duque G, Rivas D. 2007. Alendronate has an anabolic effect on bone through the differentiation of mesenchymal stem cells. J Bone Miner Res 22:1603-1611.
6. Frith JC, Monkkonen J, Auriola S, Monkkonen H, Rogers MJ. 2001. The molecular mechanism of action of the antiresorptive and anti-inflammatory drug clodronate: Evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum 44:2201-2210.
7. Giuliani N, Pedrazzoni M, Negri G, Passeri G, Impicciatore M, Girasole G. 1998. Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. Bone 22:455-461.
8. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. 1998. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339:947-952.
9. Greiner S, Kadow-Romacker A, Lubberstedt M, Schmidmaier G, Wildemann B. 2007. The effect of zoledronic acid incorporated in a poly(D,L-lactide) implant coating on osteoblasts in vitro. J Biomed Mater Res A 80:769-775.
10. Idris AI, Rojas J, Greig IR, van't Hof RJ, Ralston SH. 2008. Aminobispho-sphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcif Tissue Int 82:191-201.
11. Iwata K, Li J, Follet H, Phipps RJ, Burr DB. 2006. Bisphosphonates suppress periosteal osteoblast activity independently of resorption in rat femur and tibia. Bone 39:1053-1058.
12. Jung A, Bisaz S, Fleisch H. 1973. The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Calcif Tissue Res 11:269-280.
13. Kellinsalmi M, Monkkonen H, Monkkonen J, Leskela HV, Parikka V, Hama-lainen M, Lehenkari P. 2005. In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts. Basic Clin Pharmacol Toxicol 97:382-391.
14. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. 1998. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13:581-589.
15. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH. 2006. Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite. Bone 38:617-627.
16. 2 receptors and pyrophosphate. Endocrinology 148:4208-4216.
17. Pan B, To LB, Farrugia AN, Findlay DM, Green J, Gronthos S, Evdokiou A, Lynch K, Atkins GJ, Zannettino AC. 2004. The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone- derived cells in vitro. Bone 34:112-123.
18. Peter B, Pioletti DP, Laib S, Bujoli B, Pilet P, Janvier P, Guicheux J, Zambelli PY, Bouler JM, Gauthier 0. 2005a. Calcium phosphate drug delivery system: Influence of local zoledronate release on bone implant osteointegration. Bone 36:52-60.
19. Peter B, Zambelli PY, Guicheux J, Pioletti DP. 2005b. The effect of bispho- sphonates and titanium particles on osteoblasts: An in vitro study. J Bone Joint Surg Br 87:1157-1163.
20. Recker RR, Delmas PD, Halse J, Reid IR, Boonen S, Garcia-Hernandez PA, Supronik J, Lewiecki EM, Ochoa L, Miller P, Hu H, Mesenbrink P, Hartl F, Gasser J, Eriksen EF. 2008. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res 23:6-16.
21. Russell RG. 2006. Bisphosphonates: From bench to bedside. Ann NY Acad Sci 1068:367-401.
22. Russell RG. 2007. Bisphosphonates: Mode of action and pharmacology. Pediatrics 119 (Suppl 2): S150-S162.
23. Samadfam R, Xia Q, Goltzman D. 2007. Pretreatment with anticatabolic agents blunts but does not eliminate the skeletal anabolic response to parathyroid hormone in oophorectomized mice. Endocrinology 148:2778-2787.
24. Schindeler A, Little DG. 2005. Osteoclasts but not osteoblasts are affected by a calcified surface treated with zoledronic acid in vitro. Biochem Biophys Res Commun 338:710-716.
25. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. 2000. Bispho-sphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 82:1459-1468.
26. Silverman SL, Maricic M. 2007. Recent developments in bisphosphonate therapy. Semin Arthritis Rheum 37:1-12.
27. Tenta R, Sourla A, Lembessis P, Koutsilieris M. 2006. Bone-related growth factors and zoledronic acid regulate the PTHrP/PTH.1 receptor bioregulation systems in MG-63 human osteosarcoma cells. Anticancer Res 26:283-291.
28. Tobias JH, Chow JW, Chambers TJ. 1993. 3-Amino-1-hydroxypropylidine-1- bisphosphonate (AHPrBP) suppresses not only the induction of new, but also the persistence of existing bone-forming surfaces in rat cancellous bone. Bone 14:619-623.
29. Utting JC, Robins SP, Brandao-Burch A, Orriss IR, Behar J, Arnett TR. 2006. Hypoxia inhibits the growth, differentiation and bone-forming capacity of rat osteoblasts. Exp Cell Res 312:1693-1702.
30. van Beek E, Pieterman E, Cohen L, Lowik C, Papapoulos S. 1999. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 264:108-111.
31. von Knoch F, Jaquiery C, Kowalsky M, Schaeren S, Alabre C, Martin I, Rubash HE, Shanbhag AS. 2005. Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. Biomaterials 26:6941-6949.